Recombinant interleukin 10 for the treatment of active Crohn's disease: Lessons in biologic therapy

Gastroenterology

Volumn 119, Issue 6, 2000, Pages 1781-1783

  Bickston, S J ^a,b   Cominelli, F ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; RECOMBINANT INTERLEUKIN 10;

ANTIINFLAMMATORY ACTIVITY; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EDITORIAL; ENTERITIS; HUMAN; PRIORITY JOURNAL; REMISSION;

EID: 0034463358     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.20822     Document Type: Article

References (10)

1. Treatment of Crohn's disease at the turn of the century
2. Interleukin-10
3. Interleukin-10-deficient mice develop chronic enterocolitis
4. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice
5. -/-) mice and intestinal inflammation
6. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
7. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
8. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
9. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms
10. Ligation of intestinal epithelial CD1d induces bioactive IL-10: Critical role of the cytoplasmic tail in autocrine signaling